Avax Technologies publishes data on antimetastatic activity of its vaccine in an animal tumor model.(Brief Article)

2002 JUL 17 - (NewsRx.com & NewsRx.net) -- Avax Technologies, Inc., (AVXT) announced the publication of a paper entitled "Antimetastatic activity of hapten-modified autologous tumor cell vaccine in an animal tumor model" in the journal Cancer Immunology Immunotherapy. The paper by Margalit B. Mokyr of the University of Illinois, Chicago, a company collaborator, showed that administration of the company's hapten-modified AC Vaccine technology significantly improved relapse-free survival after removal of primary tumors in a mouse metastatic mammary tumor model compared with that of untreated animals.

Furthermore, the paper demonstrated the importance of haptenization, since animals vaccinated with unmodified tumor cells showed relapse-free survival similar to untreated animals. The experiments reported in the paper also confirmed the importance of cyclophosphamide in the dosing regimen and demonstrated the critical role of CD4[superscript]+ and CD8[superscript]+ T cells for the antimetastatic activity of the vaccine.

David Tousley, president and chief operating officer of Avax noted "We are pleased with the publication of these important findings on the original unfrozen vaccine technology, the clinical results of which have been extensively reported. These findings further validate the importance of our proprietary haptenization process. It was our intention in developing and testing this animal model, to ...